Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Serotonin toxicity of serotonergic psychedelics
Benjamin Malcolm, Kelan Thomas
Psychopharmacology (2021) Vol. 239, Iss. 6, pp. 1881-1891
Closed Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Anne Katrin Schlag, Jacob S. Aday, Iram Salam, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 3, pp. 258-272
Open Access | Times Cited: 222
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects
A. Becker, Friederike Holze, Tanja Grandinetti, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 4, pp. 886-895
Open Access | Times Cited: 131
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Jordan Sloshower, Patrick D. Skosnik, Hamideh Safi-Aghdam, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 698-706
Closed Access | Times Cited: 85
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 2
Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
David A. Bender, David J. Hellerstein
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1907-1932
Closed Access | Times Cited: 64
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1945-1976
Open Access | Times Cited: 52
Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States
Charles L. Raison, Rakesh K. Jain, Andrew Penn, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 46
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption
Emma Morton, Kimberly Sakai, Amir Ashtari, et al.
Journal of Psychopharmacology (2022) Vol. 37, Iss. 1, pp. 49-60
Open Access | Times Cited: 45
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder
Joshua D. Rosenblat, M. Ishrat Husain, Yena Lee, et al.
The Canadian Journal of Psychiatry (2022) Vol. 68, Iss. 1, pp. 5-21
Open Access | Times Cited: 38
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use
Natalie Gukasyan, Roland R. Griffiths, David B. Yaden, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 707-716
Closed Access | Times Cited: 25
Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2AReceptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter
Laura B. Kozell, Amy J. Eshleman, Tracy L. Swanson, et al.
Journal of Pharmacology and Experimental Therapeutics (2023) Vol. 385, Iss. 1, pp. 62-75
Open Access | Times Cited: 24
Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial
Jordan Sloshower, Richard J. Zeifman, Jeffrey Guss, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study
Jessica Barbut Siva, Tommaso Barba, Hannes Kettner, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 2, pp. 145-155
Open Access | Times Cited: 11
Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression
David Erritzøe, Tommaso Barba, Meg J. Spriggs, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 5, pp. 458-470
Open Access | Times Cited: 8
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)
Emma I Kopra, Jason Ferris, James Rucker, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 8, pp. 956-964
Open Access | Times Cited: 32
Naturalistic Psychedelic Use: A World Apart from Clinical Care
Nicolas G. Glynos, Christopher W. Fields, Julie Barron, et al.
Journal of Psychoactive Drugs (2022) Vol. 55, Iss. 4, pp. 379-388
Closed Access | Times Cited: 31
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines
Sean J. Belouin, Lynnette A. Averill, Jack E. Henningfield, et al.
Neuropharmacology (2022) Vol. 219, pp. 109214-109214
Open Access | Times Cited: 31
Role of Psychedelics in Treatment-Resistant Depression
Shubham Kamal, Manish K. Jha, Rajiv Radhakrishnan
Psychiatric Clinics of North America (2023) Vol. 46, Iss. 2, pp. 291-305
Closed Access | Times Cited: 20
Cardiovascular safety of psychedelic medicine: current status and future directions
Agnieszka Wsół
Pharmacological Reports (2023) Vol. 75, Iss. 6, pp. 1362-1380
Open Access | Times Cited: 20
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Abigail E. Calder, Seline Mock, Nicole Friedli, et al.
European Neuropsychopharmacology (2023) Vol. 75, pp. 1-14
Open Access | Times Cited: 19
Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
Kevin F. Boehnke, Kasey Cox, Cody Weston, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 13
Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ‐ and MES‐Induced Seizures in Mice via 5‐HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine Pathways
Mohammad Balabandian, Mohammad Amin Manavi, Ali Lesani, et al.
Pharmacology Research & Perspectives (2025) Vol. 13, Iss. 2
Open Access
Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial
A. Becker, Mélusine Humbert‐Droz, Lorenz Mueller, et al.
Clinical Pharmacology & Therapeutics (2025)
Open Access
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
Dana Kaminski, Justin P. Reinert
Annals of Pharmacotherapy (2023) Vol. 58, Iss. 8, pp. 811-826
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top